38 patents
Utility
Medical Use of Interferon-lambda for the Treatment of Fibrosis
4 Jan 24
The present invention relates to methods for the treatment of fibrosis.
Timothy Scott JOHNSON, Breda TWOMEY, Janine POWERS, Danielle E. KELLAR
Filed: 29 Jun 23
Utility
Anti-c-c Chemokine Receptor 8 (CCR8) Antibodies and Methods of Use Thereof
28 Dec 23
This present invention provides anti-C—C chemokine type 8 (CCR8) antibodies and antigen binding fragments thereof, methods of making the antibodies or antigen binding fragments thereof, and methods of use thereof to bind to human CCR8 on CCR8 expressing cells, e.g., tumor-infiltrating Treg cells, to remove CCR8 expressing cells, e.g, tumor-infiltrating Treg cells, to reduce or inhibit tumor growth and/or to treat cancer.
Susannah D. BARBEE, Shujun YUAN, Marcel MEURY, Alessandro PALUMBO, Terence WONG, Kathrin ZUBERBUHLER, Emilia FALKOWSKA
Filed: 13 Oct 21
Utility
CorrectedCD80 Extracellular Domain FC Fusion Protein Regimens
30 Nov 23
The present disclosure provides methods of administering fusion proteins comprising the extracellular domain of human cluster of differentiation 80 (CD80) and the fragment crystallizable (Fc) domain of human immunoglobulin G1 (IgG1) to a subject in need thereof, for example, a cancer patient.
Hong XIANG, Siddhartha MITRA
Filed: 4 Nov 20
Utility
B7-H4 Antibody Dosing Regimens
14 Sep 23
The present disclosure provides methods of administering antibodies and antigen-binding fragments thereof that specifically bind to human B7-H4 to a subject in need thereof, for example, a cancer patient.
Sandeep P. Inamdar, Helen L. Collins, Xiang Zhang, Hong Xiang
Filed: 27 Sep 22
Utility
Anti-CSF1R Antibody and Anti-PD-1 Antibody Combination Therapy for Cancer
6 Jul 23
Methods of treating cancer with antibodies that bind colony stimulating factor 1 receptor (CSF1R) in combination with PD-1/PD-L1 inhibitors are provided.
Brian Wong, Julie Hambleton, Robert Sikorski, Emma Masteller, Kevin Hestir, David Bellovin, Katherine E. Lewis
Filed: 21 Dec 22
Utility
FGFR2 Inhibitors Alone or In Combination with Immune Stimulating Agents In Cancer Treatment
16 Feb 23
Provided herein are uses of fibroblast growth factor receptor 2 (FGFR2) inhibitors in cancer treatment, in some cases in combination with immune stimulating agents, such as inhibitors of PD-1 or PD-L1.
Kristen PIERCE, Janine POWERS, Servando PALENCIA, Robert SIKORSKI, Majid GHODDUSI, Kartik KRISHNAN
Filed: 8 Aug 22
Utility
CD80 Extracellular Domain FC Fusion Protein Regimens
26 Jan 23
The present disclosure provides methods of administering fusion proteins comprising the extracellular domain of human cluster of differentiation 80 (CD80) and the fragment crystallizable (Fc) domain of human immunoglobulin G1 (IgG1) to a subject in need thereof, for example, a cancer patient.
Hong XIANG, Siddhartha MITRA
Filed: 11 Nov 20
Utility
B7-H4 Antibodies and Methods of Use Thereof
19 Jan 23
The present disclosure provides antibodies and antigen-binding fragments thereof that specifically bind to human B7-H4 (and optionally cynomolgus monkey, mouse, and/or rat B7-H4) and compositions comprising such antibodies or antigen-binding fragments thereof.
Charles Kaplan, Derrick Houser, Luis Borges, Gloria Brattich, David Bellovin, Felicia Kemp, Majid Ghoddusi, Nels P. Nielson, Kathy Miller, Maike Schmidt
Filed: 2 Mar 22
Utility
Bioassay for T-cell Co-stimulatory Proteins Containing FC Domains
3 Nov 22
Provided herein are components (e.g., cells and soluble proteins), systems, and methods for assessing the biological activity of soluble proteins comprising an Fc domain and a CD28-binding domain (e.g., CD80 extracellular domain Fc fusion proteins).
Luis BORGES, Artur KARASYOV, Zheng MENG, Shawn RUSSELL, Nathan SALLEE, Hongbing ZHANG, Aileen ZHOU
Filed: 17 Apr 20
Utility
PSGL-1 Antagonists and Uses Thereof
22 Sep 22
Methods of identifying and using PSGL-1 antagonists are provided.
Robert J. Johnston, Andrew Rankin, Arathi Krishnakumar, Paul O. Sheppard, Arvind Rajpal
Filed: 15 Mar 22
Utility
Pharmaceutical Formulations Containing CD80 Extracellular Domain-fc Fusion Proteins
21 Jul 22
The present disclosure provides pharmaceutical compositions comprising CD80 extracellular domain (ECD)-fragment crystallizable (Fc) fusion molecules.
Yong QUAN
Filed: 1 May 20
Utility
Afucosylated Anti-FGFR2IIIB Antibodies
2 Jun 22
The present invention provides antibodies that bind FGFR2IIIb, wherein the antibodies are afucosylated.
Thomas Harding, Kristen Pierce, Namrata Patil, Thomas Brennan, Julie Hambleton
Filed: 17 Dec 21
Utility
Antibodies Binding to Vista at Acidic pH
10 Mar 22
The present application relates to antibodies specifically binding to the V-domain immunoglobulin-containing suppressor of T-cell activation (VISTA) at acidic pH and their use in cancer treatment.
Robert J. Johnston, Arvind Rajpal, Paul O. Sheppard, Luis Borges, Andrew Rankin, Keith Sadoon Bahjat, Alan J. Korman, Xiaodi Deng, Lin Hui Su, Ginger Rakestraw, Jason R. Pinckney, David A. Critton, Guodong Chen, Richard Y. Huang, Ekaterina G. Deyanova, Michael Quigley, Hadia Lemar, Akbar Nayeem
Filed: 10 Jul 19
Utility
Anti-FGFR2 Antibodies in Combination with Chemotherapy Agents in Cancer Treatment
10 Feb 22
This application relates to uses of antibodies against fibroblast growth factor receptor 2 (FGFR2), including antibodies against the FGFR2 isoform FGFR2-IIIb (also known as FGFR2b), in treatment of certain cancers in combinations with mFOLFOX6 chemotherapy.
Helen L. Collins, James Hnatyszyn, Hong Xiang, Xiang Zhang
Filed: 2 Jul 21
Utility
CD80 Extracellular Domain FC Fusion Proteins for Treating PD-L1 Negative Tumors
3 Feb 22
The present disclosure provides methods of treating PD-L1 negative tumors, the methods comprising administering fusion proteins comprising the extracellular domain of human cluster of differentiation 80 (CD80) and the fragment crystallizable (Fc) domain of human immunoglobulin G 1 (IgG1).
Susannah D. BARBEE, Thomas BRENNAN, Barbara SENNINO
Filed: 21 Feb 20
Utility
Anti-FGFR2 Antibody Formulations
13 Jan 22
This disclosure relates to a formulation of an anti-fibroblast growth factor receptor 2 (FGFR2) antibody that, in some embodiments, is capable of being stored as a liquid, for example in a ready-to-use form, and that, in some embodiments, may be administered intravenously such as by intravenous (IV) infusion.
Isaias Prado, Chin-Yi Huang
Filed: 4 Oct 19
Utility
CD80 Extracellular Domain FC Fusion Protein Dosing Regimens
4 Nov 21
The present disclosure provides methods of administering fusion proteins comprising the extracellular domain of human cluster of differentiation 80 (CD80) and the fragment crystallizable (Fc) domain of human immunoglobulin G 1 (IgG1) to a subject in need thereof, for example, a cancer patient.
Sandeep P. INAMDAR, Kristen PIERCE, Hong XIANG, Susannah D. BARBEE
Filed: 28 Aug 19
Utility
Combination Therapy for Cancer
28 Oct 21
The present disclosure provides methods of administering antibodies and antigen-binding fragments thereof that specifically bind to human B7-H4 to a subject in need thereof, for example, a cancer patient, in combination with a PD-1/PD-L1 antagonist, such as an anti-PD-1 antibody.
Sandeep P. INAMDAR, Helen L. COLLINS, Hong XIANG, Xiang ZHANG, Neyssa MARINA
Filed: 7 Apr 21
Utility
Methods of Treating Conditions with Antibodies that Bind Colony Stimulating Factor 1 Receptor (CSF1R)
14 Oct 21
Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (CSF1R) are provided.
Julie Hambleton, Emma Masteller, James Zanghi, Robert Sikorski, Hong Xiang
Filed: 24 Feb 21
Utility
Methods of Treating Conditions with Antibodies that Bind Colony Stimulating Factor 1 Receptor (CSF1R)
9 Sep 21
Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (CSF1R) are provided.
Brian Wong, Emma Masteller, Justin Wong, Haishan Lin
Filed: 11 Feb 21